Wallace Pharmacy (Walfer Corporation), Port Charlotte, FL

Is Wallace Pharmacy (Walfer Corporation) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Wallace Pharmacy (Walfer Corporation) hold a Florida pharmacy license?

No license with this exact name and city was found in the Florida Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file covers pharmacy permits at Florida addresses. The file does list WALFER CORPORATION (dba WALLACE PHARMACY), PT CHARLOTTE, a close but not exact match shown below.

Has Wallace Pharmacy (Walfer Corporation) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Sep 20, 2022), 1 state handoff letter (Sep 20, 2022) and 1 FMD-145 letter (Sep 20, 2022) for Wallace Pharmacy (Walfer Corporation). State board actions: no Florida Board of Pharmacy action under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Walfer Corporation; Wallace Pharmacy
Former names FDA gives
The Medicine Shoppe Pharmacy
Location
Port Charlotte, FL
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 20, 2022
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 NAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 14 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Walfer Corporation dba Wallace Pharmacy (formerly The Medicine Shoppe Pharmacy), a 503A facility, with 3 dated actions.

Document
Sep 20, 2022State handoff letterState Handoff Letter Issued 9/20/2022Not linked by FDA
Sep 20, 2022Warning letter close-outWarning Letter Closeout Issued 9/20/2022Not linked by FDA
Sep 20, 2022FMD-145 letterFMD-145 Letter Issued 9/20/2022Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Walfer Corporation, Port Charlotte, FL (FEI number 3016458098), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 26, 2022No Action Indicated (NAI)Drug Quality Assurance (Drugs)30164580981171015
Mar 16, 2020Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30164580981120795

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 14 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 9, 2020 to Mar 16, 2020: 14 observations

Firm on the cover
The Medicine Shoppe Pharmacy, 3524 B Tamiami Trl, Port Charlotte, FL 33952-8100
FEI number
3016458098
Establishment type on the cover
Producer of Sterile & Non-Sterile Drugs
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

T he <R edacted B4> intended to render final product sterile was not adequate to accomplish sterilization and was <Redacted B4>

Specifically, on 3/10/20, your firm produced ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm used <Redacted B4> lot <Redacted B4> (Rx <Redacted B4> without utlizing a sterile <Redacted B4>. According to your firm's Pharmacist he failed to use a sterile <Redacted B4> for any drug products intended to be sterile that was dispensed by his firm.

Observation 2

Vermin was observed in your production area.

Specifically, from 3/9 - 3/10/20 dead ants were observed on the floor of the unclassified general production area and dead cockroaches were observed within the drawer adjacent to the <Redacted B4> hood where sterile and non-sterile drug products are produced.

Observation 3

Personnel performed aseptic processing outside of an ISO 5 classified aseptic processing area.

Specifically, on 3/10/20, your firm produced ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm used <Redacted B4> lot <Redacted B4> (Rx <Redacted B4>) in an unclassified <Redacted B4> hood. In addition, the final containers/closures used for the drug product intended to be sterile were not sterilized.

Observation 4

You did not have a HEPA filter over the area to which sterile product was exposed.

Specifically, your firm's unclassified <Redacted B4> hoods fail to contain HEPA filters. Instead, your firm is currently utilizing household air filters that can potentially shed particulates. On 3/10/20, your firm produced ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm use <Redacted B4>, lot <Redacted B4> within the <Redacted B4> hood.

Observation 5

The ISO 5 classified aseptic processing areas had difficult to clean, particle generating and visibly dirty equipment or surface.

Specifically, from 3/9 - 3/11/20, your firm's <Redacted B4> hoods <Redacted B4> adjacent to the sink <Redacted B4> nearest to the exit door) were observed cluttered with un-clean or stained balances, storage bins with miscellaneous utensils and <Redacted B4> hoods (nearest to the exit door) contains brown stains within close proximity to the <Redacted B4> household filters (potential to shed particulates). On 3/10/20, your firm's Pharmacist produced ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm used <Redacted B4> (Rx <Redacted B4> within the hood <Redacted B4>

Observation 6

Your facility was designed and/or operated in a way that permits poor flow of personnel and materials.

Specifically, your firm's facility design is inadequate for sterile production as it contains two exit doors leading to the parking lot, a sink adjacent to a <Redacted B4> hood, a kitchen dishwasher, storage of bulk drug substances and miscellaneous items stored within cardboard boxes. In addition, your firm failed to monitor pressure differentials within the unclassified production area.

Observation 7

Sinks or drains were present in the cleanroom where the ISO 5 classified aseptic processing area was located.

Specifically, from 3/9-3/11/20, a sink was observed adjacent from <Redacted B4> hood within your firm's unclassified general production area utilized for sterile and non-sterile drug production.

Observation 8

Personnel engaged in aseptic processing were observed with exposed wrists, exposed hair and exposed mouth.

Specifically, on 3/10/20, during the production of the ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm used <Redacted B4>), lot <Redacted B4> (Rx <Redacted B4> your firm's Pharmacist was observed with exposed wrists, hair and mouth as he was not donned in garb.

Observation 9

Personnel engaged in aseptic processing were observed wearing non-sterile gloves.

Specifically, on 3/10/20, during the production of ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm used <Redacted B4> , lot <Redacted B4> (Rx <Redacted B4>) your firm's Pharmacist was observed wearing non-sterile gloves.

Observation 10

Personnel manually contacted the inner surface of the container or closure.

Specifically, on 3/10/20, during the production of the ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm used <Redacted B4>, lot <Redacted B4> (Rx <Redacted B4>) your firm's Pharmacist was observed touching the inner surface of the eye dropper cap with his non-sterile gloved hands.

Observation 11

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically, your firm's Pharmacist stated he is using non-sterile <Redacted B4> and household paper towels to clean the unclassified <Redacted B4> , hoods. On 3/10/20, your firm's Pharmacist produced ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use (firm used <Redacted B4> lot <Redacted B4> (Rx <Redacted B4> within the <Redacted B4> hood.

Observation 12

Sporicidal agents were not used in your facility's cleanrooms and/or ISO 5 classified aseptic processing area.

Specifically, your firm fails to use a sporicidal agent within your firm's unclassified 's <Redacted B4> hoods. According to your firm's Pharmacist, he only uses non-sterile <Redacted B4> to clean the <Redacted B4> is when needed.

Observation 13

Unsealed, loose ceiling tiles were observed in your cleanroom.

Specifically, from 3/9 - 3/11/20, your firm's production area where ophthalmic Cyclosporin/Coconut Oil 2% eye drops for veterinary use are produced was observed to have unsealed, one cracked, and one visibly brown stained ceiling tile.

Observation 14

You produced hazardous drugs without providing adequate containment, segregation, cleaning of work surfaces, cleaning of utensils and cleaning of personnel to prevent cross-contamination.

Specifically, on 3/4/20 your firm produced the following non-sterile drug products: Estradiol 0.01 % Vaginal Cream, Rx <Redacted B4> (no lot#), expiration: 12 months (hazardous drug product) and Hydromorphone l mg/mL Suspension, Rx <Redacted B4> (no lot #), expiration: 12 months (non-hazardous drug product) within an unidentified <Redacted B4> hood without providing adequate containment, segregation, and/or cleaning of the work surfaces. In addition, your firm does not have specific procedures on how to contain and clean hazardous/potent drugs utilizing a deactivation agent or on how to handle spillage.

State board of pharmacy records

No license with this exact name and city was found in the Florida Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file covers pharmacy permits at Florida addresses. Board file.

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Close but not exact board records

These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.

Close but not exact matches

These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.